N/A N=10 Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysms
Primary: Freedom From Major Adverse Events (MAE) at Day 30 — 3; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysm
Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…
N/A N=51 Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic
Aneurysm
Primary: The Number of Subjects Free From a Major Device Event Through 1 Month Post-treatment — 50 participants — p=0.0024
Phase 2 N=23 GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta
Aortic Aneurysm, Thoracic
Primary: Freedom From Major Adverse Events and Major Device Events Through 1 Year Post-treatment — 11 Participants
N/A N=20 Endovascular Repair for the Descending Thoracic Aorta
Aorta Thoracic; Traumatic Rupture
Primary: Number of Participants With Major Adverse Events — 0 number of serious adverse events
N/A N=31 Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms
Aortic Aneurysm, Thoracic
Primary: Number of Participants With Successful Study Device Access — 31 Participants
N/A N=304 Physician-Sponsored IDE for the Talent Endoluminal Stent Graft System for the Treatment of Thoracic Lesions
Thoracic Aortic Aneurysms · Thoracic Transections · Intramural Hematoma
Primary: Number of Participants With Successful Endoluminal Treatment of Thoracic Lesion — 294 Participants
Phase 3 N=100 To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease
Aneurysm, Dissecting · Aortic Aneurysm, Thoracic
Primary: Percentage of Participants With Technically Successful Implant — 99.0 percentage of participants
N/A N=50 Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection
Type B Aortic Dissection
Primary: All-cause Mortality Incidence Through 30 Days Post-treatment — 5 participants — p=.006
N/A N=150 Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms
Aortic Aneurysm, Thoracic
Primary: Aneurysm Related Death — 4 participants
N/A N=1,366 Endovascular Exclusion of TAAA/AAA Utilizing Fenestrated/Branched Stent Grafts
Thoracoabdominal Aneurysm · Abdominal Aortic Aneurysm
Primary: Freedom From Aneurysm Rupture — 22 Participants
N/A N=160 Valor II: The Valiant Thoracic Stent Graft System Clinical Study
Thoracic Aortic Aneurysm
Primary: Percentage of Participants That Did NOT Experience Aneurysm-Related Mortality (Post-market Primary Endpoint) — 94.8 Percentage of participants
N/A N=51 Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection
Thoracic Injuries
Primary: All Cause Mortality — 4 participants
Phase 2 N=261 Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial
Aneurysm
Primary: Difference in Z-score for Rank of Maximum Transverse Diameter (MTD) Regressed on Z-score at Baseline to Assess Growth in Abdominal Aortic Aneurysm MTD Determined by CT…
Phase 2 N=55 Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Surgical Procedures
Primary: Change From Baseline to Peak in Cerebrospinal Fluid (CSF) S100 Beta Within 48 Hours Following Descending Thoracic Aorta/Thoracoabdominal Aortic Aneurysm (DTA/TAAA)…
N/A N=50 Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections
Aortic Dissection
Primary: All Cause Mortality. — 4 participants
N/A N=9 Early Feasibility of the Branched TAG® Device in the Treatment of Aortic Arch Aneurysms
Aneurysm of Aortic Arch
Primary: Number of Participants With Successful Study Device Access — 9 Participants
N/A N=15 Guo's Visceral Arteries Reconstruction: First in Man Study
Thoracoabdominal Aortic Aneurysm · Pararenal Aortic Aneurysm
Primary: Number of Participants With Major Adverse Events (MAE) Within 30 Days Postoperative — 1 participants
N/A N=110 TX2® Low Profile TAA Endovascular Graft
Aortic Aneurysm · Penetrating Ulcer · Vascular Disease
Primary: Patients With Major Adverse Events (MAE) — 2; 3 participants — p=< 0.001
N/A N=50 Study to Determine if the Valiant Stent Graft is Safe and Effective in Treating Patients Who Have a Blunt Thoracic Aortic Injury
Blunt Thoracic Aortic Injury
Primary: All-cause Mortality Within 30-days of the Index Procedure — 4 participants
N/A N=100 LSA Reconstruction With Laser Fenestration During the TEVAR
Type B Aortic Dissection
Primary: Freedom From All-cause Reintervention, All-cause Mortality and Major Adverse Events Within 30 Days After Procedure — 84 Participants
N/A N=49 Physician-Sponsored IDE for Talent Endoluminal Spring Graft System in Patients With Abdominal Aortic Aneurysms (AAA)
Abdominal Aortic Aneurysms
Primary: Number of Participants With Successful Exclusion of Abdominal Aortic Aneurysm — 49 participants' AAA
Phase 2 N=224 AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
Abdominal Aortic Aneurysm
Primary: Change in the Growth Rate of Abdominal Aortic Aneurysm — 1.77; 1.81; 1.66 mm — p=0.78
N/A N=154 GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry
Aortic Aneurysm, Thoracic · Descending Thoracic Aortic Dissection · Aortic Diseases
Primary: Number of Subjects With All-cause Mortality (Long-term) — 31 Participants
N/A N=87 Valiant Evo International Clinical Trial
Aortic Aneurysm, Thoracic
Primary: Composite Safety and Effectiveness Endpoint That is Based on the Percentage of Subjects Who Experienced (a) Access and/or Deployment Failures; and/or (b) Major Device…
N/A N=87 Valiant Evo US Clinical Trial
Aortic Aneurysm, Thoracic
Primary: Composite Safety and Effectiveness Endpoint That is Based on the Percentage of Subjects Who Experienced (a) Access and/or Deployment Failures; and/or (b) Major Device…
N/A N=55 CTAG Dissection/Trauma Post Marketing Surveillance Japan
Thoracic Aortic Aneurysm · Thoracic Aorta Injury · Thoracic Aortic Dissection
Primary: Primary Entry Tear Exclusion — 21; 26; 27; 22 Participants
N/A N=132 Biomarkers in Thoracic Aorta Surgery
Aortic Aneurysm · Thoracoabdominal Aneurysm · Aortic Dissection
Primary: Number of Total Postoperative Complications — 69 post-operative complications
N/A N=61 A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection
Aortic Diseases
Primary: Composite of Partial or No False Lumen Thrombosis, Aortic Rupture, and Aortic Dilatation — 15; 31 participants — p=<0.001
Phase 1 N=43 A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm
Primary: Number of Participants Without a Device Related Adverse Events Within 1 Month of the Study Procedure. — 36 Participants